Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease
European Respiratory Journal · 2023
DOI: 10.1183/13993003.01335-2022 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, 2023. Verfasst von Sven Schneider und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dept of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Nasal Polyps, Respiration Disorders, Asthma, Rhinitis. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background
Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) comprises the triad of chronic rhinosinusitis with nasal polyps, asthma and intolerance to NSAIDs. Dupilumab treatment, targeting the interleukin-4 (IL-4) receptor α, significantly reduces polyp burden as well as asthma symptoms. Here we aimed to investigate the effect of dupilumab on aspirin intolerance, burden of disease and nasal cytokine profiles in patients with N-ERD.
Methods
In this open-label trial, adult patients with confirmed N-ERD were treated with dupilumab for 6 months. Clinical parameters ( e.g. total polyp scores, quality of life questionnaires, smell test, spirometry), oral aspirin provocation testing and blood, nasal and urine sampling were monitored at regular intervals for up to 6 months after starting dupilumab therapy.
Results
Of the 31 patients included in the study, 30 completed both aspirin provocation tests. After 6 months of treatment with dupilumab, 23% of patients (n=7 of 30) developed complete aspirin tolerance and an additional 33% of patients (n=10 of 30) tolerated higher doses. Polyp burden was significantly reduced (total polyp score: −2.68±1.84, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dept of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, Austria.
- Dept of Dermatology, General Hospital and Medical University of Vienna, Vienna, Austria.
- Science Impuls, Seeboden, Austria.
- Dept of Dermatology, General Hospital and Medical University of Vienna, Vienna, Austria christine.bangert@meduniwien.ac.at.
ORCID-Profile: Sven Schneider, Lukas David Landegger, Christine Bangert
Förderung
- AstraZeneca
Zitieren
APA
Schneider, S., Poglitsch, K., Morgenstern, C., Quint, T., Gangl, K., Sinz, C., Bartosik, T., Campion, N. J., Liu, D. T., Landegger, L. D., Tu, A., Stanek, V., Rocha-Hasler, M., Bangert, C., & Eckl-Dorna, J. (2023). Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease. European Respiratory Journal. https://doi.org/10.1183/13993003.01335-2022
Vancouver
Schneider S, Poglitsch K, Morgenstern C, Quint T, Gangl K, Sinz C, et al. Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease. European Respiratory Journal. 2023. doi:10.1183/13993003.01335-2022
BibTeX
@article{Schneider2023,
author = {Schneider, Sven and Poglitsch, Katharina and Morgenstern, Christina and Quint, Tamara and Gangl, Katharina and Sinz, Christoph and Bartosik, Tina and Campion, Nicholas James and Liu, David Tianxiang and Landegger, Lukas David and Tu, Aldine and Stanek, Victoria and Rocha-Hasler, Marianne and Bangert, Christine and Eckl-Dorna, Julia},
title = {Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease},
journal = {European Respiratory Journal},
year = {2023},
doi = {10.1183/13993003.01335-2022}
}
EUVIMED